Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q4 2020 Earnings Conference Call February 26, 2021 8:00 AM ET Company Participants Sarah Carmody - Executive Director, Investor Relations and Corporate Communications Anna Protopapas - President and Chief Executive Officer Arvin Yang - Senior Vice President and Chief Medical Officer Timothy Lowinger - Chief Science and Technology Officer Brian DeSchuytner - Senior Vice President of Finance and Product Strategy Carla Poulson - Chief Human Resources Officer Conference ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38129 Mersana Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 04-3562403 (State ...

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q3 2020 Earnings Conference Call November 9, 2020 8:00 AM ET Company Participants Sarah Carmody ??? Executive Director, Investor Relations and Corporate Communications Anna Protopapas ??? President and Chief Executive Officer Brian DeSchuytner ??? Senior Vice President-Finance and Product Strategy Tim Lowinger ??? Chief Science and Technology Officer Chuck Miller ??? Senior Vice President-Regulatory Affairs Conference Call Participants Jonathan Chang ??? SVB Leerink ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-38129 FORM 10-Q Mersana Therapeutics, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 04-356240 ...

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q2 2020 Earnings Conference Call August 7, 2020 8:00 AM ET Company Participants Sarah Carmody ??? Executive Director, Investor Relations and Corporate Communications Anna Protopapas ??? President and Chief Executive Officer Tim Lowinger ??? Chief Science and Technology Officer Brian DeSchuytner ??? Senior Vice President Finance and Product Strategy Conference Call Participants Jonathan Chang ??? SVB Leerink Boris Peaker ??? Cowen Tom Shrader ??? BTIG Mike Ulz ??? Bai ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-38129 Mersana Therapeutics, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 04-3562403 (I. ...

XMT-1536 Interim Expansion Data from Phase 1 Study May 27, 2020 Legal Disclaimer This presentation contains "forward-looking" statements within the meaning of federal securities laws. These forward-looking statements are not statements of historical facts and are based on management's beliefs and assumptions and on information currently available to management. Forward-looking statements include information concerning the Company's business strategy and the design, progression and timing of its clinical tri ...

3549: Phase 1 expansion study of XMT-1536, a novel NaPi2b-targeting antibody-drug conjugate (ADC): Preliminary efficacy, safety, and biomarker results in patients with previously treated metastatic ovarian cancer (OC) or non-small cell lung cancer (NSCLC) Debra L. Richardson, Minal A. Barve, James F. Strauss, Susanna V. Ulahannan, Kathleen N. Moore, Erika P. Hamilton, Melissa L. Johnson, Kyriakos P. Papadopoulos, Corrine Zarwan, Charles K. Anderson, Joseph Buscema, Deborah B. Doroshow, William J. Edenfield, ...

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q1 2020 Earnings Conference Call May 8, 2020 8:00 AM ET Company Participants Sarah Carmody ??? Executive Director-Investor Relations and Corporate Communications Anna Protopapas ??? President and Chief Executive Officer Dirk Huebner ??? Chief Medical Officer Tim Lowinger ??? Chief Science and Technology Officer Brian DeSchuytner ??? Senior Vice President-Finance and Product Strategy Eva Jack ??? Chief Business Officer Conference Call Participants Jonathan Chang ??? S ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-38129 Mersana Therapeutics, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of (I.R.S. Employer incorporation or o ...